ZACdownregulation in breast tumors
- Chris Jones
© Current Science Ltd 1999
Published: 1 December 1999
Keywords6q25 breast tumors methylation tumor suppressor gene ZAC
A recently isolated cDNA encoding a new zinc finger protein has been mapped to 6q24-q25, a known hot spot for genetic loss in breast cancer. The gene has been independently isolated by two groups, and has been named as LOT (lost on transformation) and ZAC (Zinc finger protein, involved in induction of Apoptosis and control of Cell cycle progression). This area of the genome shows frequent loss in breast carcinomas, and is likely to harbor several tumor suppressor genes; however, no candidate gene has yet been assigned to this region.
To investigate ZACexpression in breast cancer cell lines and carcinomas.
The long arm of chromosome 6 shows frequent loss of genetic material in a range of solid tumors, including breast, although identification of the critical genes has thus far remained elusive. Given the antiproliferative properties and chromosomal location of ZAC on 6q, as well as the data presented here showing its downregulation in breast cancer cell lines and primary tumors, it would appear to be a strong candidate for a tumor suppressor gene. The expression data in the tumor samples are less compelling than that in the cell lines, however, and as the authors point out, confirmation using in situ hybridization and immunohistochemistry is required. Much work (in particular the proposed analysis of Zac1 knock-out mice) also remains to be done to characterize the implications of ZAC loss for breast cancer initiation and/or progression.
Eight breast cancer cell lines and a panel of unselected primary breast tumors were used in this study. Localization of ZAC in normal tissues was carried out by in situhybridization. Single strand conformation polymorphism (SSCP) and sequencing were used for mutation detection. Expression analyses utilized northern blots, the RNase protection assay, and reverse transcriptase (RT)-PCR. Gene methylation was examined using 5-azacytidine (AzaC).
In situ hybridization using an antisense ZAC probe localized the protein in normal mammary ductal cells, though not in the stroma. The most luminal cells were the most strongly labeled. SSCP analysis revealed no mutations or polymorphisms in the ZAC coding regions in a panel of 45 breast tumor samples which showed loss of heterozygosity (LOH) at the 6q23-q25 locus. This observation was confirmed by sequencing four tumor samples showing LOH with five markers in this region, as well as eight breast cancer cell lines. No ZAC mRNA was detected in five out of eight cell lines, and the remaining three showed reduced expression compared with that for normal breast tissue. Treating the cell lines with the methylation-interfering agent AzaC resulted in the expression of the ZAC protein in three out of the five ZAC-negative cell lines. The other two remained negative. The three cell lines which were ZAC-positive under control conditions displayed enhanced ZAC expression after AzaC treatment. ZAC expression in unselected primary breast tumors was highly variable, although it was notably reduced in several of the samples.
ZAC encodes a new zinc finger protein with antiproliferative properties, and is located on chromosome 6q24-q25 This is a region thought to harbor at least one tumor suppressor gene important in breast cancer progression. ZAC is expressed in normal mammary tissue, and has been shown here to localize to the most luminal layer of the epithelial cells, from which the majority of breast tumors arise. ZAC expression was lost from or downregulated in eight breast cancer cell lines as well as in several primary tumors compared with expression in normal mammary tissue. This loss of expression was at due at least in part to gene methylation, and not to homozygous deletion of the ZAC coding region. All the evidence points to ZAC being a good candidate for a tumor suppressor gene of potential importance in breast cancer progression.